STOCK TITAN

[Form 4] Hims & Hers Health, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Hims & Hers Health (HIMS) reported an insider transaction by its Chief Financial Officer. On 10/17/2025, the CFO exercised stock options for 7,785 shares at $5.01 and 3,807 shares at $11.53, then sold 11,592 Class A shares at a weighted average price of $57.1275. These trades were made under a Rule 10b5-1 trading plan adopted on May 21, 2025.

Following the transactions, the CFO beneficially owned 70,232 Class A shares directly. Derivative holdings following the transactions included 174,380 options (exercise price $5.01; expiration 02/23/2032) and 56,169 options (exercise price $11.53; expiration 03/01/2033).

Hims & Hers Health (HIMS) ha riportato una transazione interna da parte del suo Chief Financial Officer. Il CFO, il 17/10/2025, ha esercitato opzioni su azioni per 7.785 azioni a 5,01 $ e 3.807 azioni a 11,53 $, poi ha venduto 11.592 azioni Class A ad un prezzo medio ponderato di 57,1275 $. Queste operazioni sono state effettuate nell'ambito di un piano di trading Rule 10b5-1 adottato il 21 maggio 2025.

A seguito delle transazioni, il CFO deteneva direttamente 70.232 azioni Class A. Le posizioni derivate dopo le transazioni includevano 174.380 opzioni (prezzo di esercizio 5,01 $; scadenza 23/02/2032) e 56.169 opzioni (prezzo di esercizio 11,53 $; scadenza 01/03/2033).

Hims & Hers Health (HIMS) informó una operación interna por parte de su Director Ejecutivo Financiero. El 17/10/2025, el CFO ejerció opciones sobre acciones por 7.785 acciones a 5,01 $ y 3.807 acciones a 11,53 $, y luego vendió 11.592 acciones Clase A a un precio medio ponderado de 57,1275 $. Estas operaciones se realizaron bajo un plan de negociación Rule 10b5-1 adoptado el 21 de mayo de 2025.

Después de las transacciones, el CFO poseía directamente 70.232 acciones Clase A. Las posiciones derivadas tras las transacciones incluían 174.380 opciones (precio de ejercicio 5,01 $; vencimiento 23/02/2032) y 56.169 opciones (precio de ejercicio 11,53 $; vencimiento 01/03/2033).

Hims & Hers Health (HIMS)가 최고재무책임자(CFO)의 내부자 거래를 보고했습니다. 2025년 10월 17일, CFO는 주식매수선택권으로 7,785주를 5.01달러에 행사했고 3,807주를 11.53달러에 행사한 후 가중평균가 57.1275달러로 11,592주(Class A 주식)을 매도했습니다. 이 거래들은 2025년 5월 21일에 채택된 Rule 10b5-1 트레이딩 플랜에 따라 이루어졌습니다.

거래 후 CFO는 직접적으로 70,232주(Class A 주식)를 보유했습니다. 거래 이후의 파생보유는 행사가격 5.01달러인 174,380주(만료 2032년 2월 23일)와 행사가 11.53달러인 56,169주(만료 2033년 3월 1일)를 포함했습니다.

Hims & Hers Health (HIMS) a signalé une transaction d’initié par son directeur financier. Le 17/10/2025, le CFO a exercé des options d’achat pour 7 785 actions à 5,01 $ et 3 807 actions à 11,53 $, puis a vendu 11 592 actions de catégorie A à un prix moyen pondéré de 57,1275 $. Ces transactions ont été réalisées dans le cadre d’un plan de trading Rule 10b5-1 adopté le 21 mai 2025.

À la suite des transactions, le CFO détenait directement 70 232 actions de catégorie A. Les positions dérivées après les transactions comprenaient 174 380 options (prix d’exercice 5,01 $; expiration 23/02/2032) et 56 169 options (prix d’exercice 11,53 $; expiration 01/03/2033).

Hims & Hers Health (HIMS) meldete eine Insider-Transaktion seines Chief Financial Officer. Am 17.10.2025 hat der CFO Aktienoptionen für 7.785 Aktien zu 5,01 $ und 3.807 Aktien zu 11,53 $ ausgeübt und anschließend 11.592 Class-A-Aktien zu einem durchschnittlich gewichteten Preis von 57,1275 $ verkauft. Diese Geschäfte wurden im Rahmen eines am 21. Mai 2025 verabschiedeten Rule 10b5-1-Handelsplans durchgeführt.

Nach den Transaktionen hielt der CFO direkt 70.232 Class-A-Aktien. Derivatepositionen nach den Transaktionen umfassten 174.380 Optionen (Ausübungspreis 5,01 $; Verfall 23.02.2032) und 56.169 Optionen (Ausübungspreis 11,53 $; Verfall 01.03.2033).

Hims & Hers Health (HIMS) أبلغت عن صفقة insider من قبل المدير المالي التنفيذي. في 17/10/2025، نفّذ المدير المالي التنفيذي خيارات شراء أسهم لـ 7,785 سهمًا بسعر 5.01 دولارات و3,807 أسهم بسعر 11.53 دولارًا، ثم باع 11,592 سهمًا من فئة A بمعدل سعر مُوزون قدره 57.1275 دولارًا. جاءت هذه الصفقات في إطار خطة تداول Rule 10b5-1 المعتمدة في 21 مايو 2025.

بعد الصفقات، امتلك المدير المالي التنفيذي 70,232 سهمًا من فئة A بشكل مباشر. كما شملت المراكز المشتقة بعد الصفقات 174,380 خيارًا (سعر الإسناد 5.01 دولار؛ انتهاء الصلاحية 23/02/2032) و56,169 خيارًا (سعر الإسناد 11.53 دولار؛ انتهاء الصلاحية 01/03/2033).

Hims & Hers Health (HIMS) 报告了首席财务官的内部人交易。2025年10月17日,CFO以5.01美元行使7,785股股票期权,以11.53美元行使3,807股股票期权,然后以加权平均价格57.1275美元出售11,592股A类股票。这些交易是在2025年5月21日通过的Rule 10b5-1交易计划下进行的。

交易后,CFO直接拥有70,232股A类股票。交易后的衍生头寸包括174,380份期权(行使价5.01美元;到期日2032-02-23)和56,169份期权(行使价11.53美元;到期日2033-03-01)。

Positive
  • None.
Negative
  • None.

Insights

Analyzing...

Hims & Hers Health (HIMS) ha riportato una transazione interna da parte del suo Chief Financial Officer. Il CFO, il 17/10/2025, ha esercitato opzioni su azioni per 7.785 azioni a 5,01 $ e 3.807 azioni a 11,53 $, poi ha venduto 11.592 azioni Class A ad un prezzo medio ponderato di 57,1275 $. Queste operazioni sono state effettuate nell'ambito di un piano di trading Rule 10b5-1 adottato il 21 maggio 2025.

A seguito delle transazioni, il CFO deteneva direttamente 70.232 azioni Class A. Le posizioni derivate dopo le transazioni includevano 174.380 opzioni (prezzo di esercizio 5,01 $; scadenza 23/02/2032) e 56.169 opzioni (prezzo di esercizio 11,53 $; scadenza 01/03/2033).

Hims & Hers Health (HIMS) informó una operación interna por parte de su Director Ejecutivo Financiero. El 17/10/2025, el CFO ejerció opciones sobre acciones por 7.785 acciones a 5,01 $ y 3.807 acciones a 11,53 $, y luego vendió 11.592 acciones Clase A a un precio medio ponderado de 57,1275 $. Estas operaciones se realizaron bajo un plan de negociación Rule 10b5-1 adoptado el 21 de mayo de 2025.

Después de las transacciones, el CFO poseía directamente 70.232 acciones Clase A. Las posiciones derivadas tras las transacciones incluían 174.380 opciones (precio de ejercicio 5,01 $; vencimiento 23/02/2032) y 56.169 opciones (precio de ejercicio 11,53 $; vencimiento 01/03/2033).

Hims & Hers Health (HIMS)가 최고재무책임자(CFO)의 내부자 거래를 보고했습니다. 2025년 10월 17일, CFO는 주식매수선택권으로 7,785주를 5.01달러에 행사했고 3,807주를 11.53달러에 행사한 후 가중평균가 57.1275달러로 11,592주(Class A 주식)을 매도했습니다. 이 거래들은 2025년 5월 21일에 채택된 Rule 10b5-1 트레이딩 플랜에 따라 이루어졌습니다.

거래 후 CFO는 직접적으로 70,232주(Class A 주식)를 보유했습니다. 거래 이후의 파생보유는 행사가격 5.01달러인 174,380주(만료 2032년 2월 23일)와 행사가 11.53달러인 56,169주(만료 2033년 3월 1일)를 포함했습니다.

Hims & Hers Health (HIMS) a signalé une transaction d’initié par son directeur financier. Le 17/10/2025, le CFO a exercé des options d’achat pour 7 785 actions à 5,01 $ et 3 807 actions à 11,53 $, puis a vendu 11 592 actions de catégorie A à un prix moyen pondéré de 57,1275 $. Ces transactions ont été réalisées dans le cadre d’un plan de trading Rule 10b5-1 adopté le 21 mai 2025.

À la suite des transactions, le CFO détenait directement 70 232 actions de catégorie A. Les positions dérivées après les transactions comprenaient 174 380 options (prix d’exercice 5,01 $; expiration 23/02/2032) et 56 169 options (prix d’exercice 11,53 $; expiration 01/03/2033).

Hims & Hers Health (HIMS) meldete eine Insider-Transaktion seines Chief Financial Officer. Am 17.10.2025 hat der CFO Aktienoptionen für 7.785 Aktien zu 5,01 $ und 3.807 Aktien zu 11,53 $ ausgeübt und anschließend 11.592 Class-A-Aktien zu einem durchschnittlich gewichteten Preis von 57,1275 $ verkauft. Diese Geschäfte wurden im Rahmen eines am 21. Mai 2025 verabschiedeten Rule 10b5-1-Handelsplans durchgeführt.

Nach den Transaktionen hielt der CFO direkt 70.232 Class-A-Aktien. Derivatepositionen nach den Transaktionen umfassten 174.380 Optionen (Ausübungspreis 5,01 $; Verfall 23.02.2032) und 56.169 Optionen (Ausübungspreis 11,53 $; Verfall 01.03.2033).

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Okupe Oluyemi

(Last) (First) (Middle)
2269 CHESTNUT STREET, #523

(Street)
SAN FRANCISCO CA 94123

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Hims & Hers Health, Inc. [ HIMS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 10/17/2025 M(1) 7,785 A $5.01 78,017 D
Class A Common Stock 10/17/2025 M(1) 3,807 A $11.53 81,824 D
Class A Common Stock 10/17/2025 S(1) 11,592 D $57.1275(2) 70,232 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $5.01 10/17/2025 M(1) 7,785 (3) 02/23/2032 Class A Common Stock 7,785 $0 174,380 D
Stock Option (right to buy) $11.53 10/17/2025 M(1) 3,807 (4) 03/01/2033 Class A Common Stock 3,807 $0 56,169 D
Explanation of Responses:
1. The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025 by the Reporting Person.
2. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $56.93 - $57.315. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
3. 25% of the options will vest on the twelve (12) month anniversary of the Vesting Commencement Date of January 24, 2022. The balance of the shares shall vest in a series of thirty-six (36) successive equal monthly installments measured from the twelve (12) month anniversary of the Vesting Commencement Date, subject to optionholder's continuous Service (as defined in the Plan) as of each such vesting date.
4. The options are subject to a service-based vesting requirement, which shall be satisfied over a 4-year period, with 1/48th of the options vesting monthly, beginning on April 1, 2023.
Remarks:
/s/ Kimberly Mather, Attorney-in-Fact for Oluyemi Okupe 10/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did HIMS disclose in this Form 4?

The CFO exercised options for 7,785 shares at $5.01 and 3,807 shares at $11.53 on 10/17/2025, then sold 11,592 shares at a $57.1275 weighted average.

Was the HIMS CFO’s trade under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 plan adopted on May 21, 2025.

How many HIMS shares did the CFO sell and at what price?

11,592 Class A shares at a weighted average price of $57.1275, with sales between $56.93 and $57.315.

How many HIMS shares does the CFO own after these transactions?

70,232 Class A shares directly, following the reported transactions.

What derivative securities remain after the transactions?

174,380 options at $5.01 expiring 02/23/2032 and 56,169 options at $11.53 expiring 03/01/2033.

What is the earliest transaction date on the Form 4 for HIMS?

10/17/2025.
Hims & Hers Health Inc

NYSE:HIMS

HIMS Rankings

HIMS Latest News

HIMS Latest SEC Filings

HIMS Stock Data

11.16B
202.99M
10.63%
88.99%
33.02%
Household & Personal Products
Services-offices & Clinics of Doctors of Medicine
Link
United States
SAN FRANCISCO